Yang Yin Fu Zheng Jie Du Therapy in HBV Related Hepatocellular Carcinoma Induced Anemia (YYFZJDTIHBVRHCIA)

• Status: Recruiting
• Trial end date: 2023-06-30
• Target enrollment: 0
• Participant gender: All

Summary

Clinical research of Yang Yin Fu Zheng Jie Du therapy in HBV related hepatocellular carcinoma induced anemia. The purpose of this study is to observe the efficacy of routine medical care combined with Yang Yin Fu Zheng Jie Du therapy for patients belong to HBV-HCC induced anemia.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beijing Ditan Hospital

Criteria

Inclusion Criteria:

• Meet the criteria of hepatocellular carcinoma

• Patients who tested positive for hepatitis B surface antigen (HBsAg) for >6 months

• Meet the criteria of anemia

• Ages Eligible for Study: ≤75 years old;

• Informed consent from the patient.

Exclusion Criteria:

• Patients with upper gastrointestinal bleeding within 3 months before enrollment;

• History of blood transfusion within 3 months before enrollment;

• Patient with other chronic hepatopathy, such as AIH, NAFLD, ALD;

• Serious problem of heart, lung, or kidney with severe dysfunction;

• Pregnant or child breast feeding women;

• Mental or cognitive disorders;

• Participating in other drug trials;

• Who are allergic to the study drug.